University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3L-17-5


A multicenter, non-randomized, open-label dose escalation Phase Ib study of regorafenib in combination with pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) with no prior systemic therapy.

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Marile Garcia, Coordinator, Yanli Wang, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.